From GlobeNewswire:

Novo Nordisk, Omega Therapeutics, Inc., and Cellarity Inc. have entered into separate research collaborations. The Omega collaboration will focus on developing an epigenomic controller for obesity management, while the Cellarity collaboration will aim to develop a small molecule therapy for MASH. This marks the first two programs signed under the partnership between Novo Nordisk and Flagship Pioneering. Novo Nordisk will reimburse R&D costs and the companies are eligible to receive up to 532 million US dollars in upfront and milestone payments, as well as tiered royalties. These collaborations highlight the commitment to advancing new treatment options for people living with cardiometabolic diseases and are a part of the larger effort to leverage novel technologies to create innovative medicines.



Read more: Novo Nordisk enters into research collaborations with Omega